Developing the EAVE III platform for future health crises. (2023)
Attributed to:
Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II)
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(23)00626-6
PubMed Identifier: 37839426
Publication URI: http://europepmc.org/abstract/MED/37839426
Type: Journal Article/Review
Volume: 23
Parent Publication: The Lancet. Infectious diseases
Issue: 11
ISSN: 1473-3099